In some glioblastoma CSCs, they observed VEGFR2-Nrp1 recycling and a pool of active VEGFR2 within a cytosolic compartment, which they postulate contributes to the resistance of these cells to anti-VEGF therapy with bevacizumab. This evidence concerns the gene NRP1 and glioblastoma.